This study is aimed at better understanding the potential molecular alterations underlying HDAC inhibitors in breast cancer via bioinformatics methods and in vitro experiments, providing a rationale to explore the clinical value of HDACi in solid cancer. The gene discussed is HDAC9; the disease is breast cancer.